Evotec
Sebastian Schmeier is a skilled bioinformatics professional with extensive experience in leadership and research roles within academia and industry. Currently serving as Group Leader and Team Lead for Bioinformatics at Evotec since July 2020, Sebastian previously held positions at the Maurice Wilkins Centre for Molecular Biodiscovery as Associate Investigator and Affiliate Investigator from March 2014 to July 2020. At Massey University, from December 2012 to July 2020, Sebastian was a Research Group Leader and Senior Lecturer in Bioinformatics & Genomics. Additional roles include Bioinformatics Specialist/Advisor at New Zealand Genomics Limited, Postdoctoral Fellow at King Abdullah University of Science and Technology, and PhD Student at the South African National Bioinformatics Institute, among others. Sebastian's academic credentials include a PhD in Bioinformatics from the University of the Western Cape, as well as an MSc and BSc in Bioinformatics from Freie Universität Berlin.
This person is not in the org chart
This person is not in any teams
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.